Sica 2004.

Methods	Randomized, double‐blind, placebo‐controlled, parallel study. After 2‐3 weeks of single‐blind placebo run‐in, eligible participants were randomized to 1 of the treatments for 8 weeks. Participants who were randomized to propranolol 120 mg or 160 mg would start at 80 mg then force titrated to respective dose in the next 2 weeks. Participants who were randomized to propranolol 640 mg/day started at 160 mg and then up titrated to 640 mg in the next 3 weeks
Participants	Inclusion criteria: DBP 96‐114 mmHg during 2 readings while sitting Exclusion criteria: pregnancy, lactating, renal artery stenosis, gastrointestinal diseases, kidney or liver diseases, cardiac diseases within the last 6 months, asthma, COPD, nonallergic bronchospasms, insulin‐dependent diabetes, concomitant administration of drugs that affect BP
Interventions	Propranolol 80 mg once daily, propranolol 120 mg once daily, propranolol 160 mg once daily, propranolol 640 mg once daily, placebo
Outcomes	SBP, DBP, HR, plasma concentration, safety
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information
Allocation concealment (selection bias)	Unclear risk	No information
Blinding (performance bias and detection bias) All outcomes	High risk	Placebo pills were taken at the same frequency
Incomplete outcome data (attrition bias) Primary and secondary outcomes	Unclear risk	No information
Selective reporting (reporting bias)	Low risk	All outcomes reported